Esoxybutynin

Drug Profile

Esoxybutynin

Alternative Names: S-Oxybutynin

Latest Information Update: 11 Jul 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sepracor
  • Class Antispasmodics; Small molecules
  • Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Urinary incontinence

Most Recent Events

  • 21 Jun 2001 Phase-III clinical trials for Urinary incontinence in USA (PO)
  • 30 Aug 2000 Clinical data have been added to the adverse events and Genitourinary Disorders therapeutic trials sections
  • 23 Jun 2000 Sepracor has successfully completed a phase II dose-ranging trial in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top